WO2003080121A1 - Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels - Google Patents

Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels Download PDF

Info

Publication number
WO2003080121A1
WO2003080121A1 PCT/IB2002/000689 IB0200689W WO03080121A1 WO 2003080121 A1 WO2003080121 A1 WO 2003080121A1 IB 0200689 W IB0200689 W IB 0200689W WO 03080121 A1 WO03080121 A1 WO 03080121A1
Authority
WO
WIPO (PCT)
Prior art keywords
dendrimer
composition according
inflammatory
disease
composition
Prior art date
Application number
PCT/IB2002/000689
Other languages
English (en)
Inventor
Abhay Singh Chauhan
Prakash Vamanrao Diwan
Narendra Kumar Jain
Kondapuram Vijaya Raghavan
Original Assignee
Council Of Scientific And Industrial Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Scientific And Industrial Research filed Critical Council Of Scientific And Industrial Research
Priority to AU2002249486A priority Critical patent/AU2002249486A1/en
Priority to PCT/IB2002/000689 priority patent/WO2003080121A1/fr
Publication of WO2003080121A1 publication Critical patent/WO2003080121A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition et l'utilisation de cette composition, laquelle présente une activité anti-inflammatoire et comprend un monomère macromoléculaire monodispersé, tel qu'un dendrimère renfermant une pluralité de groupes terminaux, ou des molécules liées/complexées à des fractions médicamenteuses présentant une activité anti-inflammatoire ou favorisant l'activité anti-inflammatoire. L'invention concerne également l'utilisation de cette composition dans une préparation pharmaceutique destinée à traiter une maladie ou des états pathologiques associés à une inflammation.
PCT/IB2002/000689 2002-03-26 2002-03-26 Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels WO2003080121A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002249486A AU2002249486A1 (en) 2002-03-26 2002-03-26 Macromolecular compounds as potential anti-inflammatory agents
PCT/IB2002/000689 WO2003080121A1 (fr) 2002-03-26 2002-03-26 Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/000689 WO2003080121A1 (fr) 2002-03-26 2002-03-26 Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels

Publications (1)

Publication Number Publication Date
WO2003080121A1 true WO2003080121A1 (fr) 2003-10-02

Family

ID=28053138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000689 WO2003080121A1 (fr) 2002-03-26 2002-03-26 Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels

Country Status (2)

Country Link
AU (1) AU2002249486A1 (fr)
WO (1) WO2003080121A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041310A1 (fr) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation de conjugues de dendrimere et de glucide chimiquement bien definis
WO2009046446A2 (fr) 2007-10-05 2009-04-09 Wayne State University Dendrimères pour la libération prolongée de composés
WO2010013086A1 (fr) * 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique Dendrimères phosphorylés en tant que médicaments anti-inflammatoires
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
US10106565B2 (en) 2008-08-01 2018-10-23 Centre National De La Recherche Scientifique Phosphorylated dendrimers as antiinflammatory drugs
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US10918720B2 (en) 2014-08-13 2021-02-16 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US11612660B2 (en) 2019-12-04 2023-03-28 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898033A (en) * 1995-06-07 1999-04-27 Swadesh; Joel K. Antigen-processing cell-targeted conjugates
US6190650B1 (en) * 1994-06-15 2001-02-20 Biomolecular Research Institute Ltd. Antiviral dendrimers
US20010006817A1 (en) * 1998-02-19 2001-07-05 Daniel W. Pack Cell delivery compositions
US20010034333A1 (en) * 1998-12-30 2001-10-25 Kosak Kenneth M. Cyclodextrin polymer compositions for use as drug carriers
WO2001091816A1 (fr) * 2000-06-02 2001-12-06 The Regents Of The University Of Michigan Systemes d'administration a membranes biocompatibles et bioerodables

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190650B1 (en) * 1994-06-15 2001-02-20 Biomolecular Research Institute Ltd. Antiviral dendrimers
US5898033A (en) * 1995-06-07 1999-04-27 Swadesh; Joel K. Antigen-processing cell-targeted conjugates
US20010006817A1 (en) * 1998-02-19 2001-07-05 Daniel W. Pack Cell delivery compositions
US20010034333A1 (en) * 1998-12-30 2001-10-25 Kosak Kenneth M. Cyclodextrin polymer compositions for use as drug carriers
WO2001091816A1 (fr) * 2000-06-02 2001-12-06 The Regents Of The University Of Michigan Systemes d'administration a membranes biocompatibles et bioerodables

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER C.: "Synthetic polymer systems in drug delivery.", EXPERT OPINION ON EMERGING DRUGS, (2001) 6/2 (345-363)., XP008011196 *
LIU, M. ET AL: "Water-soluble dendritic unimolecular micelles: Their potential as drug delivery agents", JOURNAL OF CONTROLLED RELEASE (2000), 65(1-2), 121-131, XP002223307 *
MILHEM O M ET AL: "Polyamidoamine Starburst dendrimers as solubility enhancers.", INTERNATIONAL JOURNAL OF PHARMACEUTICS. NETHERLANDS 20 MAR 2000, vol. 197, no. 1-2, 20 March 2000 (2000-03-20), pages 239 - 241, XP002223306, ISSN: 0378-5173 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041310A1 (fr) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation de conjugues de dendrimere et de glucide chimiquement bien definis
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
US9283247B2 (en) 2007-06-22 2016-03-15 Genzyme Corporation Chemically modified dendrimers
US9611357B2 (en) 2007-06-22 2017-04-04 Genzyme Corporation Chemically modified dendrimers
US10463609B2 (en) 2007-10-05 2019-11-05 Wayne State University Dendrimers for sustained release of compounds
WO2009046446A2 (fr) 2007-10-05 2009-04-09 Wayne State University Dendrimères pour la libération prolongée de composés
US11684569B2 (en) 2007-10-05 2023-06-27 Wayne State University Dendrimers for sustained release of compounds
EP2214646B1 (fr) * 2007-10-05 2021-06-23 Wayne State University Dendrimères pour la libération prolongée de composés
US10106565B2 (en) 2008-08-01 2018-10-23 Centre National De La Recherche Scientifique Phosphorylated dendrimers as antiinflammatory drugs
WO2010013086A1 (fr) * 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique Dendrimères phosphorylés en tant que médicaments anti-inflammatoires
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US10918720B2 (en) 2014-08-13 2021-02-16 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US11612660B2 (en) 2019-12-04 2023-03-28 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Also Published As

Publication number Publication date
AU2002249486A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
US20070014757A1 (en) Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
JP6144383B2 (ja) 薬物送達系の構成成分の一時的コンジュゲーションのための調整可能な生分解性リンカー分子、及びそれを用いて調製される薬物送達系
Gothwal et al. Lactoferrin coupled lower generation PAMAM dendrimers for brain targeted delivery of memantine in aluminum-chloride-induced Alzheimer’s disease in mice
Cheng et al. Dendrimers as drug carriers: applications in different routes of drug administration
Singh et al. Folate and folate− PEG− PAMAM Dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice
TWI305538B (fr)
Cao et al. Synthesis and unimolecular micelles of amphiphilic dendrimer-like star polymer with various functional surface groups
JP5131971B2 (ja) 水溶性非ペプチド性低分子薬物含有ナノ粒子
Zhang et al. pH-sensitive assembly of light-harvesting dendrimer zinc porphyrin bearing peripheral groups of primary amine with poly (ethylene glycol)-b-poly (aspartic acid) in aqueous solution
Mondjinou et al. Synthesis of 2-hydroxypropyl-β-cyclodextrin/pluronic-based polyrotaxanes via heterogeneous reaction as potential Niemann-Pick type C therapeutics
JP5349318B2 (ja) ステロイド類の高分子結合体
ES2236518T3 (es) Micelas polimericas unimoleculares provistas de un nucleo interior ionizable.
Satija et al. Pharmaceutical and biomedical potential of surface engineered dendrimers
Gao et al. Stereoselective stabilization of polymeric vitamin E conjugate micelles
Qi et al. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol
AU2008359989A1 (en) Drug carriers
JP2011173908A (ja) 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
Liu et al. Dendrimers in oral drug delivery application: current explorations, toxicity issues and strategies for improvement
Grillaud et al. Polycationic adamantane-based dendrons of different generations display high cellular uptake without triggering cytotoxicity
ES2902082T3 (es) Inhibidores de MetAP2 Fumagillol conjugados a polímero o modificados para mejorar o restaurar la sensibilidad a la insulina
JP2001522351A (ja) 新規な脂肪酸誘導体
US20140030341A1 (en) Polymers and methods for the treatment of pain
Cao et al. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release
WO2003080121A1 (fr) Composes macromoleculaires utilises comme agents anti-inflammatoires potentiels
Alfei et al. Synthesis and characterization of fourth generation polyester‐based dendrimers with cationic amino acids‐modified crown as promising water soluble biomedical devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP